新华制药子公司获布洛芬颗粒药品注册证

Group 1 - The core point of the article is that Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for ibuprofen granules from the National Medical Products Administration [1] Group 2 - The approval of the ibuprofen granules indicates a significant regulatory milestone for the company, potentially enhancing its product portfolio and market competitiveness [1] - This development may lead to increased revenue opportunities for the company as it expands its offerings in the pharmaceutical market [1] - The registration of ibuprofen granules aligns with the company's strategy to innovate and diversify its pharmaceutical products [1]